Elke T. Prada-Aristizabal

Elke T. Prada-Aristizabal

Planegg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Mucosal IFNλ1 mRNA-based immunomodulation effectively reduces SARS-CoV-2 induced mortality in mice.

Mucosal IFNλ1 mRNA-based immunomodulation effectively reduces SARS-CoV-2 induced mortality in mice.

Journal: EMBO reports

Published: January 16, 2024

Primary Aldosteronism: KCNJ5 Mutations and Adrenocortical Cell Growth.

Primary Aldosteronism: KCNJ5 Mutations and Adrenocortical Cell Growth.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: August 27, 2019

Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures.

Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures.

Journal: Endocrinology

Published: May 30, 2019

The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.

The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.

Journal: Endocrine-related cancer

Published: June 07, 2018

Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors.

Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors.

Journal: Endocrine-related cancer

Published: March 09, 2018

Comparative Genomics and Transcriptome Profiling in Primary Aldosteronism.

Comparative Genomics and Transcriptome Profiling in Primary Aldosteronism.

Journal: International journal of molecular sciences

Published: February 15, 2018

Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.

Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.

Journal: Endocrine connections

Published: October 02, 2017

GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.

GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.

Journal: Neuroendocrinology

Published: April 30, 2017

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.

Journal: PloS one

Published: April 11, 2017

The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.

The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.

Journal: PloS one

Published: December 02, 2016

The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.

The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.

Journal: Neuroendocrinology

Published: October 10, 2016

Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways.

Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways.

Journal: PloS one

Published: July 23, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026